BDTX-1535, a fourth generation EGFR inhibitor, targeting intrinsic and acquired resistance mutations in NSCLC. (October 2022) - Lucas, M.; Merchant, M.; O'Connor, M.; Smith, S.; Trombino, A.; Waters, N.; Eathiraj, S.; Buck, E.